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Abstract 10 
Several lines of evidence indicate that during transformation epithelial cancer cells can acquire 11 
mesenchymal features via a process called epithelial-to-mesenchymal transition (EMT). This process 12 
endows cancer cells with increased invasive and migratory capacity, enabling tumour dissemination 13 
and metastasis. EMT is associated with a complex metabolic reprogramming, orchestrated by EMT 14 
transcription factors, which support the energy requirements of increased motility and growth in 15 
harsh environmental conditions. The discovery that mutations in metabolic genes such as FH, SDH 16 
and IDH activate EMT provided further evidence that EMT and metabolism are intertwined. In this 17 
review, we discuss the role of EMT in cancer and the underpinning metabolic reprogramming. We 18 
also put forward the hypothesis that, by altering chromatin structure and function, metabolic 19 
pathways engaged by EMT are necessary for its full activation. 20 
 21 
Background 22 
In the last decades, cancer research uncovered the many enabling features of tumours cells [1]. 23 
Among these, activation of epithelial-to-mesenchymal transition (EMT), a process where epithelial 24 
cancer cells acquire mesenchymal features, is emerging as key determinant of cancer cell invasion and 25 
metastasis [2-4]. To metastasise, cancer cells acquire the ability to erode the extracellular matrix, the 26 
motility to extravasate into the blood stream, and the plasticity to grow in a different tissue. In all 27 
these phases, nutrient supply can be limited and cancer cells experience varying degree of stress [5]. 28 
Accordingly, metastatic cells fine-tune their metabolism to adapt to the ever-changing environment 29 
[6, 7]. In line with this observation, part of the genetic reprogramming orchestrated by EMT affects 30 
the expression of metabolic genes, regulating glucose, lipids, glutamine, and nucleotide metabolism. 31 
Yet, to what extent EMT rewires the metabolic network is still unclear. The recent discovery that 32 
oncogenic mutations of metabolic enzymes such as fumarate hydratase (FH), succinate 33 
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dehydrogenase (SDH) and isocitrate dehydrogenase (IDH) drive EMT [8-10] indicates that the 34 
connection between EMT and metabolism is deeper than anticipated. Indeed, these works revealed 35 
that components of the metabolic network can directly affect chromatin structure and function, 36 
impinging on signalling cascades required for the full activation of EMT [11, 12]. In this review, we 37 
describe the role of EMT in tumorigenesis, how EMT affects metabolism, and how, in turn, 38 
dysregulation of metabolic genes affect the execution of EMT. 39 
The epithelial-to-mesenchymal transition in cancer  40 
In tissues, epithelial cells are organised in compact layers anchored to the basal lamina. During 41 
transformation, some of these cells lose their epithelial features and acquire a mesenchymal 42 
phenotype through a process defined as epithelial-to-mesenchymal-transition (EMT). This process is 43 
characterised by profound transcriptional [13] and epigenetic changes [14, 15] that lead to the loss of 44 
cell-to-cell junctions and the acquisition of a motile and migratory phenotype, enabling the invasion 45 
of the basal lamina, which eventually may lead to metastasis. At the molecular level, EMT is dictated 46 
by a network of transcription factors (EMT-TFs) that directly or indirectly represses one of the key 47 
epithelial markers, E-Cadherin [13, 16]. These EMT-TFs belongs to various family of chromatin 48 
interacting family of proteins, including Snail (Snai1 and Snai2), bHLH (Twist1 and Twist2), and zinc 49 
finger and E-box binding (Zeb1 and Zeb2). Cross-activation of EMT by other oncogenic stimuli and the 50 
identification of non-canonical EMT-TFs such as Kruppel-like-factor (KLF8), the homebox proteins 51 
goosecoid (GSC) or fork-head protein (FOXC2), contributes to the great complexity of EMT regulation 52 
[13, 16]. Moreover, recent evidence has shown that microRNAs are also potent regulators of EMT, 53 
affecting the expression of multiple targets of this cascade [17].  54 
The role of the EMT-TFs in invasion and metastasis has been extensively investigated [16]. In 55 
vivo experiments using a spontaneous squamous cell carcinoma mouse model showed that the 56 
expression of the EMT-TF Twist1 is sufficient to trigger EMT and the subsequent dissemination of 57 
cancer cells into the blood stream. Interestingly, the colonisation of target tissues by these metastatic 58 
cells is driven by a mesenchymal-to-epithelial transition (MET) and requires suppression of Twist1 [18]. 59 
Other works identified a primary role of the EMT in breast cancer progression. For instance, Twist1 60 
controls the ability of aggressive breast 4T1 cells to migrate in vitro and to metastasise to the lung in 61 
vivo [19]. The role of Twist1 in early dissemination and metastasis was also corroborated in human 62 
epidermal growth factor receptor 2 (Her2)-positive mammary cancer cells. It was shown that in early 63 
lesions in mouse breast, a subpopulation of cells that express high levels of Twist1, low levels of E-64 
cadherin, and markers of Wnt signalling activation, invade the adjacent tissue and lead to early 65 
dissemination and subsequent mestastasis [20]. Moreover, in mouse skin squamous cell carcinoma, 66 
Twist1 is required in both early and late stages of tumour progression in a gene dosage- dependent 67 
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manner [21]. Other EMT-TF are directly involved in breast cancer metastasis. For instance, the 68 
expression of Snai1 in a mouse model of breast cancer activates the dissemination of cancer cells and 69 
its deletion dramatically impairs the formation of metastasis [22]. The impact of SNAI1 activation in 70 
the malignancy of breast tumours has been further confirmed by the discovery that the discoidin 71 
domain receptor 2 (DDR2), a protein expressed in ductal breast carcinomas, drives invasion in vitro 72 
and metastasis in vivo through the nuclear stabilisation of Snai1, via phosphorylation mediated by 73 
extracellular related kinase 2 (ERK2) [23]. Even though a series of convincing works established the 74 
involvement of EMT in metastasis formation, its real importance in tumour evolution is still 75 
questioned. For instance, two groups recently showed that the EMT is dispensable for metastasis in a 76 
model of pancreatic [24] and breastcancer [25]. These results suggest that the role of EMT in cancer 77 
progression is likely tissue-specific and that it might be implicated in other features of cancer. Indeed, 78 
it has recently emerged that EMT, via the expression of EMT-TFs, enables stemness in cancer cells [2, 79 
16]. For instance, an orchestrated signal mediated by SNAI2 and SOX9 induces a stem state and 80 
promotes tumorigenesis in mammary luminal cells [26], while the ectopic expression of TWIST1 or 81 
SNAI1 results in the expression of stem markers in human immortalised mammary cells [27]. 82 
Moreover, ZEB1-mediated suppression of miR200 favours the expression of polycomb repressor 83 
protein Bmi1 [28, 29] and Suz12 [30], two regulators of self-renewal and stemness in breast cells. 84 
Further work showed that the acquisition of stem-like properties through EMT activation is involved, 85 
at least in part, in both chemoresistance [31, 32] and tumour dormancy [31, 33-35]. These two 86 
prominent features of cancer therapy may be interlinked. Seminal work using an elegant in vivo model 87 
to trace EMT lineage during metastasis showed that EMT-positive cells are responsible for recurrence 88 
of lung metastasis after chemotherapy with cyclophosphamide, suggesting that chemoresistance, 89 
EMT and dormancy may be part of the same pathway [25].  90 
EMT activation induces a metabolic rewiring  91 
Recent findings indicate that mesenchymal cancer cells have different metabolic needs compared 92 
their epithelial counterparts, to satisfy the metabolic demands of increased motility and invasion. Yet, 93 
how EMT regulates metabolism is still poorly understood. In the effort to corroborate this link, Shaul 94 
and colleagues analysed the expression of metabolic genes in high-grade carcinomas expressing 95 
mesenchymal markers using publically available data from almost 1000 cancer cell lines. They found 96 
that these mesenchymal cells exhibit high expression levels of 44 metabolic genes. These genes were 97 
found upregulated also upon induction of EMT by expression of Twist1 in human mammary epithelial 98 
cells. Among these enzymes, Dihydropyrimidine dehydrogenase (DPYD), an enzyme involved in 99 
pyrimidine catabolism, was required for EMT, both in vitro and in vivo [36] (Figure 1). Importantly, 100 
exogenous dihydropyrimidines are sufficient to rescue EMT after silencing of DPYD, suggesting that 101 
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these metabolites are a limiting factor during the EMT. However, the how they regulate EMT is 102 
currently unknown. 103 
Overall, these results suggested that metabolic rewiring is required to complete the 104 
reprogramming orchestrated by EMT. In further support of these findings, it was found that SNAI1 105 
expression represses the glycolytic enzyme fructose-1,6-bisphosphatase 1 (FBP1), favouring glucose 106 
uptake and the diversion of glycolytic carbons towards biosynthetic pathways, including the pentose 107 
phosphate shunt (Figure 1). Interestingly, FBP1 loss impairs respiration and the activity of respiratory 108 
chain complex I [37]. Activation of glycolysis by EMT was also observed in breast and prostate cancer 109 
cells, where it is required for both cytoskeleton remodelling and increasing cell traction [38]. Glycolysis 110 
is targeted by EMT also in non-small cell lung cancer cells (NSCLC), where ZEB1 activate the expression 111 
of glucose transporter 3 (GLUT3) [39]. However, the metabolic reprogramming upon EMT in NSCLC is 112 
controversial. For instance, the treatment of NSCLC with TGF-β induces a shift from glycolysis to 113 
OXPHOS and leads to an overall increase in amino acids, in particular in glutamate, via a higher flux of 114 
carbons through the TCA cycle. Mechanistically, this shift from glycolysis to OXPHOS is achieved by a 115 
selective repression of pyruvate dehydrogenase kinase 4 during EMT [40]. Finally, EMT induction by 116 
TGF-β in colon cancer cells elicits the nuclear translocation of pyruvate kinase M2 (PKM2) and the 117 
silencing of PKM2 prevents EMT triggering by TGF-β in these cells [41] (Figure 1). 118 
Other metabolic pathways are targeted during EMT, including lipid metabolism (Figure 1). For 119 
example, EMT activation by either TNFα or TGF-β favours the accumulation of unsaturated 120 
triacylglycerides in DU145 prostate cancer cells [42]. Furthermore, the activation of EMT by 121 
overexpression of SNAI1 suppresses transcriptional regulators of the lipogenesis carbohydrate-122 
responsive element binding protein (ChREBP) leading to the silencing of both fatty acid synthase 123 
(FASN) and acetyl-CoA carboxylase (ACC) [43]. Finally, another pathway required during EMT is 124 
glutaminolysis (Figure 1): lung cancer cells that undergo an EMT become increasingly sensitive to 125 
Glutaminase-1 (GLS1) inhibitors [44].  126 
As discussed above, EMT activation is involved in both chemoresistance and tumour dormancy. 127 
Even though the role of metabolism in these processes is largely unknown, recent works suggest that 128 
metabolic rewiring can be important in both chemoresistance and tumour dormancy. For instance, 129 
EMT-positive breast cells that are responsible for recurrent lung metastasis after chemotherapy 130 
increased the expression of metabolic enzymes such as drug transporters, aldehyde dehydrogenase 131 
(ALDHs), cytochrome P450s, and enzymes of glutathione metabolism [25] (Figure 1). Likely, these 132 
metabolic changes protect the cells from oxidative stress experienced during therapy. Furthermore, 133 
deletion of Twist1 or Snai1 in chemoresistant pancreatic cancer cells increase the expression of a 134 
nucleosides transporter, which leads to increase uptake of the anticancer drug gemcitabine [24]. The 135 
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link between EMT, metabolic alterations, and tumour dormancy remains mainly indirect. It is widely 136 
known that during tumour dormancy, cancer cells undergo proliferative arrest and enter quiescence 137 
[34]. Therefore, it not surprising that this change in proliferation rate is accompanied by a metabolic 138 
rewiring. For instance, pancreatic ductal cancer cells surviving after oncogene ablation acquire stem-139 
like traits and are dependent on oxidative phosphorylation for survival [45]. In addition, quiescent 140 
leukaemia stem cells (LSC) rely on mitochondrial metabolism: targeting the oxidative phosphorylation 141 
through BCL-2 inhibition is sufficient to eradicate LSC population [46]. However, the impact of EMT-142 
TFs in regulating these metabolic alterations during dormancy is largely unknown and it might be 143 
related to the dynamic shift between EMT and MET that occurs on tumour circulating cells [47].  144 
Overall, these results suggest that metabolic reprogramming is instrumental to the phenotypic shift 145 
observed during the EMT. Whether these metabolic changes are simply required to fulfil the energy 146 
requirements of more aggressive cells or to support some of the signalling cascades involved in this 147 
process is still unknown.  148 
Metabolic reprogramming activates the epithelial- to-mesenchymal transition 149 
Recent evidence suggests that the link between EMT and metabolism is mutual and, in some 150 
circumstances, alterations of metabolism can drive EMT. The next part of the review describes how 151 
the dysregulation of metabolic pathways is associated with EMT induction. These findings are 152 
summarised in Figure 2. 153 
Glycolysis 154 
Aerobic glycolysis is the most distinctive metabolic alteration of cancer cells [1, 48] but the role of 155 
glycolytic enzymes in the induction of EMT has emerged only in the last years. Phosphoglucose 156 
isomerase (PGI) is a glycolytic enzyme that converts glucose-6P to fructose 6-P. This enzyme was found 157 
to be secreted by cancer cells and to act as cytokine, taking the name of autocrine motility factor 158 
(AMF). Overexpression of PGI/AMF causes a NF-kB-dependent stabilisation of ZEB1 and ZEB2 in breast 159 
cancer cells [49] and ectopic expression in normal epithelial breast MCF10A triggers EMT [50]. 160 
Importantly, suppression of PGI/AMF leads to reverse MET in lung fibrosarcoma [51] and endometrial 161 
cancer cells [52]. As described above, the expression of the glycolytic enzyme fructose-1,6-162 
biphosphatase (FBP1) blocks the induction of EMT mediated by SNAI1 in luminal breast cells. The 163 
silencing of FBP1 favours EMT also in gastric cells in vitro [53]. Other glycolytic enzymes are involved 164 
in EMT induction. For instance, the silencing of Aldolase A (ALDOA), an enzyme that converts fructose-165 
1,6-bisphosphate to glyceraldehydes-3-phosphate and hydroxy-acetone, impairs lung squamous 166 
carcinoma cell motility and tumorigenesis and this phenomenon is associated with repression of 167 
mesenchymal markers [54]. Furthermore, silencing of glyceraldehyde-3-phosphate dehydrogenase 168 
(GAPDH) inhibits EMT by repressing SNAI1 in colon cancer [55]. Finally, overexpression of lactate 169 
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dehydrogenase (LDH), the enzyme that converts pyruvate to lactate, leads to increased migration and 170 
invasion in bladder cancer cells [56].  171 
Mitochondrial metabolism  172 
Mitochondrial dysfunction is a key feature of cancer and has been frequently associated with 173 
increased aggressiveness and metastatic potential [57, 58]. Yet, the mechanistic link between 174 
mitochondrial dysfunction and EMT have only recently been investigated. In 2014 it was shown that 175 
mitochondrial dysfunction induced by depletion of mitochondrial DNA in breast cells leads to 176 
profound morphological and molecular changes that resembles EMT, including increased expression 177 
of EMT-TFs, metalloproteases and suppression of E-cadherin, triggered by a Calcineurin A (CaN)-178 
dependent mechanism [59]. In support of this finding, we recently found that the downregulation of 179 
mitochondrial genes is a common feature of highly aggressive cancers, and that it significantly 180 
correlates with the activation of EMT across 21 different types of cancer [60]. More recently, we and 181 
others have demonstrated that EMT is a key signature of tumours harbouring mutations in the 182 
Tricarboxylic Acid (TCA) cycle enzymes FH, SDH and IDH [8-10]. 183 
Fumarate hydratase is the enzyme that converts fumarate to malate. Mutations of this enzyme lead 184 
to Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) [61] and other tumour types, including 185 
paragangliomas and pheochromocytomas [62, 63], whilst FH deletions have been found in 186 
neuroblastoma [64]. FH-mutant renal tumours are highly aggressive and metastasise even when small 187 
[65]. However, the mechanisms underpinning this aggressiveness are still under investigation. We 188 
recently demonstrated that FH-deficient cells exhibit a striking mesenchymal phenotype, linked with 189 
the expression of an EMT signature [8]. The link between FH and EMT was also observed in 190 
nasopharyngeal carcinoma, where FH is transcriptionally repressed by the lymphoid-specific helicase 191 
(LSH) [66]. Mechanistically, we found that fumarate, which accumulates in FH-deficient cells and 192 
tumours, is responsible for the induction of EMT by inhibiting the TET-dependent demethylation of 193 
the anti-metastatic microRNA miR200 [8], known inhibitors of both SNAI2 [67] and ZEB1 [68] (Figure 194 
3).  195 
Another TCA cycle enzyme implicated in EMT is Succinate dehydrogenase (SDH), a component of the 196 
respiratory chain that converts succinate to fumarate. SDH mutations have been described in 197 
pheochromocytomas and paragangliomas [69-72], sporadic renal cancer [73] and gastrointestinal 198 
stromal tumours [74, 75]. A recent study revealed that human metastatic pheochromocytomas and 199 
paragangliomas harbouring SDHB mutations are invasive and exhibit activation of EMT–TFs such as 200 
SNAI1 and SNAI2, suggesting the induction of EMT in these tumours [10] . Consistently, it was shown 201 
that loss of SDHB in chromaffin cells induces these EMT-TFs and leads to the epigenetic silencing of 202 
keratin-19 [76, 77]. Importantly, the migratory phenotype of these cells is reversed by the use of a 203 
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DNA methylation inhibitor, decitabine. The link between SDHB deficiency and EMT was also shown in 204 
colorectal cancer, where the silencing of SDHB promotes cell migration and invasion in a TGF-/SNAI1-205 
mediated-process [78], and also in ovarian cancer [79]. Finally, loss of the assembly factor SDH5 [80], 206 
induces EMT in lung cancer cells and metastasis in-vivo through activation of a glycogen-synthase 207 
kinase (GSK-3)--catenin axis [81]. Although these studies did not focus on the accumulation of 208 
succinate as a mediator of EMT, we recently found that succinate, similarly to fumarate, can induce 209 
the epigenetic suppression of miR200 and subsequent EMT induction in Sdhb-deficient epithelial 210 
kidney cells [8] (Figure 3).  211 
Other TCA cycle enzymes recently appeared in the spotlight of cancer biology and EMT are Isocitrate 212 
Dehydrogenases (IDHs), enzymes involved in the oxidative decarboxylation of isocitrate to alpha-213 
ketoglutarate (aKG). Three isoforms of IDH have been identified: cytosolic IDH1 and mitochondrial 214 
IDH2 are NADP+-dependent enzymes, while mitochondrial IDH3 is a NAD+-dependent protein. 215 
Heterozygous mutations in either IDH1 or IDH2 have been found in gliomas and leukaemia [82-84]. 216 
IDH1 and IDH2 mutations are neomorphic and lead to the production of 2-hydroxyglutarate (2HG), 217 
which was shown to induce EMT. Similar to what was described for FH and SDH deficient cells, EMT in 218 
IDH-mutant cells is driven by alterations of the miR200-Zeb1 axis (Figure 3). This phenomenon was 219 
observed in breast tumours [9], and in colorectal cancer cells [9, 85].  220 
Finally, another TCA cycle enzyme associated with EMT is citrate synthase (CS), the enzyme that 221 
catalyses the first committed step of the TCA cycle. Silencing of CS induces morphological and 222 
molecular changes in human cervical carcinoma cells that resemble EMT, and promotes metastasis in 223 
vivo. The molecular mechanisms responsible for this phenotype are not clear, but it is possible that 224 
the mitochondrial dysfunction observed in these cells is involved [86]. However, more recent 225 
experiments indicate that CS is upregulated in other tumour types such as ovarian cancers and that 226 
its silencing impairs both motility and invasion of tumour cells in vitro [87]. Therefore, the role of CS 227 
in tumour progression is still unclear and it might be tissue-dependent.  228 
Lipid metabolism 229 
Several recent reports support the connection between lipid metabolism and EMT. For instance, the 230 
overexpression of acetyl-CoA synthetase (ACSL1 and ACSL4) and steroyl-CoA desaturase (SCD) can 231 
activate EMT in colorectal cancer, leading to increased migration, invasion and colony formation in 232 
vitro. Importantly, the expression of these three enzymes is associated with poor prognosis in stage II 233 
colorectal cancer patients [88]. In addition, elevated fatty acid uptake via CD36 activates a Wnt-234 
dependent EMT in hepatocellular carcinoma (HCC) [89]. Of note, in human oral cancer cells CD36-235 
positive cells are responsible for cancer initiation and metastasis in vivo. However, in the latter model 236 
the EMT is not involved in the formation of metastasis [90]. Other enzymes of lipid metabolism have 237 
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been identified as EMT regulators. For instance, silencing of ATP citrate lyase (ACL) reverses EMT in 238 
lung cancer and impairs stemness in both lung and breast cells by SNAI1 repression [91]. Moreover, 239 
silencing of acetyl-CoA carboxylase 2 (ACC2) reverted the EMT transition triggered by glucose stress, 240 
triglyceride deposit and malonyl-CoA accumulation in kidneys [92]. Interestingly, treatment of cancer 241 
cells with fatty acids such as arachidonic or linoleic acid elicits an EMT that is downstream of the 242 
oncogenic cascades mediated by SRC, NF-kB and FAK [93, 94]. 243 
Glutaminolysis 244 
Most cancer cells depend on glutamine utilisation [48], and the role of glutaminolysis in EMT has been 245 
recently investigated. The inhibition of glutaminolysis by targeting GLS1 impairs in vivo metastasis 246 
through repression of SNAI1 [95]. On the contrary, the expression of GLS2, the mitochondrial isoform 247 
of glutaminase, inversely correlates with stage, tumour size, and prognosis in HCC. However, this 248 
phenomenon is independent of GLS2 glutaminase activity and involves the GLS2-mediated 249 
stabilisation of the EMT-related microRNA miR-34a via the Dicer complex [96]. These results suggest 250 
that the effects of glutamine catabolism on EMT might be context-dependent and more work is 251 
necessary to elucidate the importance of glutaminolysis in this process. 252 
Conclusions and future perspective 253 
EMT is a fundamental biological process involved in development, fibrosis, and wound healing [4]. 254 
Recent evidence indicates that this process is also involved in tumour initiation and metastasis. EMT 255 
elicits a complex phenotypic switch that endows cancer cells with ability to survive during invasion, 256 
dissemination, and metastasis. This flexibility is achieved at least in part by the rewiring of the 257 
metabolic network. As discussed above, EMT, via EMT-TFs, orchestrates profound metabolic changes 258 
that allow the cell to sustain the energy needs of a cancer cell in an ever-changing tumour micro 259 
environment. Yet, the role of metabolism in EMT seems to go beyond these simple enabling features. 260 
Indeed, the observation that dysregulation of cellular metabolism, in some circumstances, drives EMT 261 
indicates that parts of the metabolic network could act as a core component of the signalling cascade 262 
elicited by the EMT (Figure 4). The data discussed in this review corroborate this hypothesis and 263 
indicate that specific metabolic alterations could lead to chromatin changes that are required for the 264 
activity of EMT-TFs. Several questions arise. For instance, it is still unclear why different sources of 265 
mitochondrial dysfunction converge on EMT. In an interesting parallel, EMT induction is associated 266 
with bypass of oncogene –induced senescence [97]. Given that senescence is a common outcome of 267 
metabolic stress [98] it is possible that induction of EMT could provide cells with the sufficient 268 
plasticity to survive and proliferate in the presence of metabolic defects or under nutrient stress. In 269 
this scenario, metastasis could be seen as a strategy to explore novel, and more favourable, metabolic 270 
niches, and increased motility the means to this goal. Another outstanding question in the field is to 271 
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what extent the EMT observed in metabolically-impaired cells contributes to tumorigenesis. The fact 272 
that EMT is the most enriched gene signature in FH and SDH-deficient cells seems to support a driving 273 
role of EMT in these tumours. It would be important to validate this hypothesis by assessing 274 
tumorigenesis in FH- or SDH-deficient models where EMT-TFs are ablated. Finally, the fact that EMT 275 
shows unexpected metabolic facets offers interesting therapeutical perspectives (Fig.4). Indeed, EMT 276 
could be potentially reverted by targeting specific metabolic enzymes, or targeting the metabolism-277 
dependent epigenetic reprogramming, eventually limiting cancer metastasis. Consistently, inhibitors 278 
of mutant IDH were shown to revert glioma cells to a more differentiated state [99], and the DNA 279 
methylation inhibitor, decitabine, impairs the invasive phenotype of SDH-deficient cells [77]. Along 280 
this strategy, a recent screening was designed to identify small molecules that could revert the 281 
mesenchymal phenotype of cancer cells activating E-cadherin transcription. Interestingly, it was found 282 
that protein kinase A (PKA) activation by increasing cyclic AMP (cAMP) levels, is sufficient to trigger a 283 
mesenchymal-to-epithelial transition (MET) in aggressive breast cancer cells, through activation of the 284 
histone demethylases PHF2. cAMP is a key second messenger and its levels are tightly controlled by 285 
the energy state of cells [100]. Therefore, it is tempting to speculate that metabolic alterations, 286 
through regulation of cAMP levels, are necessary for full EMT activation and that altering metabolism 287 
could be a tempting strategy to modify cell phenotype and, more importantly, aggressive features of 288 
cancer.  289 
Overall, in this review we provided compelling evidence that EMT and metabolism are intertwined. 290 
Understanding the underpinning molecular determinants of this relation is revealing novel insights 291 
into how tumours are formed and disseminate, and will potentially provide novel targets for targeting 292 
metastasis, the major killer in cancer.  293 
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Figure legends 692 
Fig.1 EMT controls metabolic reprogramming 693 
EMT transcription factors (EMT-TFs) control the expression of metabolic genes of different pathways 694 
such as glycolysis, lipid metabolism, and mitochondrial metabolism, and glutaminolysis. Specifically, 695 
EMT-TFs suppress the expression of fructose-1,6-bisphosphatase 1 (FBP1), fatty acid synthase (FASN), 696 
acetyl-coA carboxylase (ACC), nucleoside transporter, and pyruvate dehydrogenase kinase 4 (PDK4), 697 
whilst enhance the expression of dihydropyrimidine dehydrogenase (DPYD), glutaminase 1 (GLS1), 698 
enzymes of glutathione metabolism, cytochrome P450, aldehyde dehydrogenases, and glucose 699 
transporter 3 (GLUT3). Red dashed arrows indicate the metabolic nodes regulated by EMT-TFs. 700 
TCA=tricarboxylic acid cycle. 701 
Fig.2 Metabolic genes control EMT. 702 
Aberrant expression of metabolic enzymes of glycolysis (orange), lipid metabolism (purple), 703 
glutaminolysis (blue), mitochondrial metabolism (green), leads to EMT. Red dashed arrows indicate 704 
the link between specific metabolic pathway/metabolites and EMT. ACC=acetyl-CoA carboxylase; 705 
ACL=ATP citrate lyase; ACSL=acetyl-CoA synthetase; ALDOA=aldolase A; CaN=calcineurin A; CI-706 
CV=respiratory chain complexes I-V; CoQ=coenzyme Q; CS=citrate synthase; CytC=cytochrome C; 707 
FBP1=fructose-1,6-bisphosphatase 1; FH=fumarate hydratase; GAPDH=glyceraldehyde-3-phosphate 708 
dehydrogenase; GLS=glutaminase; IDH=isocitrate dehydrogenase; LDHA=lactic dehydrogenase A; PGI 709 
=phosphoglucose isomerase; PKM2=pyruvate kinase M2; SCD=steroyl-CoA desaturase; 710 
SDH=succinate dehydrogenase. 711 
Fig.3 EMT activation by mutations in FH, SDH and IDH requires epigenetic reprogramming. 712 
Schematic representation of how mitochondrial metabolites accumulated upon mutation of the 713 
indicated TCA cycle enzymes activate the EMT. A common pathway affected by these metabolites is 714 
the epigenetic suppression of a family of antimetastatic microRNAs, miR200, via the inhibition of 715 
histone demethylases (KDMs) and DNA demethylases (TETs). Of note, in the case of 2HG, the 716 
suppression of miR200 is indirect, and occurs via activation of Zeb1/2. See the text for more details. 717 
FH=fumarate hydratase; SDH=succinate dehydrogenase; IDH=isocitrate dehydrogenase.  718 
Fig.4 Integration between oncogenic signalling, metabolic transformation, and epigenetic 719 
reprogramming during EMT 720 
EMT requires the coordinated activation of multiple cellular processes, here represented as gears 721 
within a clockwork. Each of these components are essential for the full activation of EMT. As 722 
consequence, the inhibition of parts of this clockwork hampers the full activation of the EMT. For 723 
20 
 
instance, inhibition of mutant IDH, or activation of PKA can block EMT. PKA=protein kinase A; 724 
IDH=isocitrate dehydrogenase. 725 
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